Jiangsu Hansoh and GSK Receive FDA Breakthrough Designation for B7-H3 Targeted ADC in Small-Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a prominent Chinese pharmaceutical company, and its UK...
HKG: 3692
Jiangsu Hansoh Pharmaceutical and GSK Win FDA Breakthrough Therapy Designation for B7-H3 Targeted ADC in Small-Cell Lung Cancer
LONDON/HONG KONG—Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), in collaboration with UK-based GSK plc (NYSE:...
Hansoh Pharmaceutical Secures Rights to Lupeng’s BTK Inhibitor LP-168 in Licensing Deal
Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...
Hansoh Pharmaceutical’s EGFR Inhibitor Ameile Files for Adjuvant Therapy Approval with NMPA
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading biopharmaceutical company based in China, has...
Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China
Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a...
Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting...
Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...
Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that...
Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval
Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...
GSK Secures Exclusive Rights to Hansoh’s ADC Candidate HS-20093 in New Licensing Deal
GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing...
Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules
Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...
Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials
Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug,...
Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20105 Clinical Study in Solid Tumors
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a China-based pharmaceutical company, has announced that it...
Hansoh Pharmaceutical Receives NMPA Approval for Generic Ofev (Nintedanib)
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received marketing...
Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...
Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Hansoh Pharmaceutical’s Ibrexafungerp NDA Accepted for Review by China’s NMPA for VVC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that the National Medical Products...
Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case
Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against...